Integral Health Asset Management LLC trimmed its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 29.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 900,000 shares of the biotechnology company's stock after selling 375,000 shares during the quarter. Integral Health Asset Management LLC owned about 1.82% of REGENXBIO worth $6,957,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after buying an additional 2,510 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in REGENXBIO in the 4th quarter worth approximately $54,000. Dynamic Technology Lab Private Ltd bought a new position in REGENXBIO in the 4th quarter worth approximately $79,000. Teacher Retirement System of Texas grew its holdings in REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after buying an additional 2,088 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new position in REGENXBIO in the 4th quarter worth approximately $97,000. 88.08% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
RGNX has been the subject of a number of recent analyst reports. Leerink Partners set a $24.00 price objective on REGENXBIO in a report on Tuesday, March 18th. Raymond James started coverage on REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. The Goldman Sachs Group cut their target price on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. HC Wainwright cut their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, March 17th. Finally, Morgan Stanley upped their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, REGENXBIO currently has a consensus rating of "Moderate Buy" and an average target price of $31.63.
View Our Latest Report on RGNX
Insider Activity
In other news, Director Kenneth T. Mills sold 20,602 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director now owns 475,103 shares in the company, valued at approximately $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.79% of the company's stock.
REGENXBIO Price Performance
Shares of NASDAQ:RGNX traded up $0.15 on Wednesday, reaching $8.33. 1,188,144 shares of the company traded hands, compared to its average volume of 863,289. REGENXBIO Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $16.85. The company's 50 day moving average is $7.43 and its 200-day moving average is $7.99. The stock has a market capitalization of $417.47 million, a PE ratio of -1.66 and a beta of 1.11.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. As a group, analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.
REGENXBIO Profile
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
